Transdermal Scopolamine Precipitating Narrow-Angle Glaucoma

Research output: Contribution to journalLetter

11 Citations (Scopus)

Abstract

To the Editor: A transdermal TM-V (scopolamine) programmed-delivery system has recently been released as treatment for the prevention of nausea and vomiting associated with motion sickness. The National Registry of Drug-Induced Ocular Side Effects has had five case reports of adverse ocular effects secondary to this drug-delivery system. Two of the reported cases were bilateral mydriasis causing bilateral narrow-angle glaucoma. One patient required surgery; the other was treated medically. Since this medication is now often used on ships by those susceptible to motion sickness, physicians aboard ships should have available 4 per cent topical ocular pilocarpine and 0.25 per.

Original languageEnglish (US)
Pages (from-to)1079
Number of pages1
JournalNew England Journal of Medicine
Volume307
Issue number17
DOIs
StatePublished - Oct 21 1982

Fingerprint

Angle Closure Glaucoma
Scopolamine Hydrobromide
Motion Sickness
Ships
Mydriasis
Pilocarpine
Drug Delivery Systems
Nausea
Vomiting
Registries
Physicians
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Transdermal Scopolamine Precipitating Narrow-Angle Glaucoma. / Fraunfelder, Frederick (Fritz).

In: New England Journal of Medicine, Vol. 307, No. 17, 21.10.1982, p. 1079.

Research output: Contribution to journalLetter

@article{444252aad93445f5aafdea3fc83ab090,
title = "Transdermal Scopolamine Precipitating Narrow-Angle Glaucoma",
abstract = "To the Editor: A transdermal TM-V (scopolamine) programmed-delivery system has recently been released as treatment for the prevention of nausea and vomiting associated with motion sickness. The National Registry of Drug-Induced Ocular Side Effects has had five case reports of adverse ocular effects secondary to this drug-delivery system. Two of the reported cases were bilateral mydriasis causing bilateral narrow-angle glaucoma. One patient required surgery; the other was treated medically. Since this medication is now often used on ships by those susceptible to motion sickness, physicians aboard ships should have available 4 per cent topical ocular pilocarpine and 0.25 per.",
author = "Fraunfelder, {Frederick (Fritz)}",
year = "1982",
month = "10",
day = "21",
doi = "10.1056/NEJM198210213071713",
language = "English (US)",
volume = "307",
pages = "1079",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "17",

}

TY - JOUR

T1 - Transdermal Scopolamine Precipitating Narrow-Angle Glaucoma

AU - Fraunfelder, Frederick (Fritz)

PY - 1982/10/21

Y1 - 1982/10/21

N2 - To the Editor: A transdermal TM-V (scopolamine) programmed-delivery system has recently been released as treatment for the prevention of nausea and vomiting associated with motion sickness. The National Registry of Drug-Induced Ocular Side Effects has had five case reports of adverse ocular effects secondary to this drug-delivery system. Two of the reported cases were bilateral mydriasis causing bilateral narrow-angle glaucoma. One patient required surgery; the other was treated medically. Since this medication is now often used on ships by those susceptible to motion sickness, physicians aboard ships should have available 4 per cent topical ocular pilocarpine and 0.25 per.

AB - To the Editor: A transdermal TM-V (scopolamine) programmed-delivery system has recently been released as treatment for the prevention of nausea and vomiting associated with motion sickness. The National Registry of Drug-Induced Ocular Side Effects has had five case reports of adverse ocular effects secondary to this drug-delivery system. Two of the reported cases were bilateral mydriasis causing bilateral narrow-angle glaucoma. One patient required surgery; the other was treated medically. Since this medication is now often used on ships by those susceptible to motion sickness, physicians aboard ships should have available 4 per cent topical ocular pilocarpine and 0.25 per.

UR - http://www.scopus.com/inward/record.url?scp=0019973653&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019973653&partnerID=8YFLogxK

U2 - 10.1056/NEJM198210213071713

DO - 10.1056/NEJM198210213071713

M3 - Letter

C2 - 7121520

AN - SCOPUS:0019973653

VL - 307

SP - 1079

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 17

ER -